VB10: Completed Phase I/IIa enrollment

Vaccibody completed enrollment of 12 patients with CIN grade 2 lesions in the Phase I portion of an open-label, German Phase I/IIa trial evaluating 2 dosing schedules of 3 mg intramuscular VB10.16. In...